Дело T-***/**: *****************, Съдебно решение от **.**.2019 г.

Текст

... in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)

In Case T‑377/18,

Intercept Pharma Ltd, established in Bristol (United Kingdom),

Intercept Pharmaceuticals, Inc., established in New York, New York (United States),

represented by L. Tsang, J. Mulryne, E. Amos and H. Kerr-Peterson, Solicitors, and F. Campbell, Barrister,

applicants,

v

European Medicines Agency (EMA), represented initially by S. Marino, S. Drosos, A. Rusanov and T. Jabłoński, and subsequently by S. Marino, S. Drosos, T. Jabłoński, R. Pita and G. Gavriilidou, acting as Agents,

defendant,

ACTION under Article 263 TFEU for the annulment of EMA decision ASK-40399 of 15 May 2018, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document containing information submitted in the context of an application for marketing authorisation for the medicinal product Ocaliva,

THE GENERAL COURT (Second Chamber),

composed of M. Prek, President, F. Schalin (Rapporteur) and M.J. Costeira, Judges,

Registrar: E. Artemiou, Administrator,

having regard to the written part of the procedure and further to the hearing on 12 February 2019,

gives the following

Judgment

Background to the dispute

1. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company and the parent company of Intercept Pharma Ltd (‘the applicants’). The applicants are ...